{
    "root": "2f88053c-63fd-243c-e063-6294a90aa0cb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levetiracetam",
    "value": "20250304",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6437"
        }
    ],
    "indications": {
        "text": "levetiracetam indicated treatment partial-onset seizures patients 1 month age older ( 1.1 ) levetiracetam indicated adjunctive therapy treatment : myoclonic seizures patients 12 years age older juvenile myoclonic epilepsy ( 1.2 ) primary generalized tonic-clonic seizures patients 6 years age older idiopathic generalized epilepsy ( 1.3 )",
        "doid_entities": [
            {
                "text": "juvenile myoclonic epilepsy (DOID:4890)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4890"
            },
            {
                "text": "myoclonic epilepsy (DOID:308)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_308"
            },
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            },
            {
                "text": "idiopathic generalized epilepsy (DOID:1827)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1827"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "oral solution pediatric patients body weight \u2264 20 kg ( 2.1 ) pediatric patients , weight-based dosing oral solution calibrated measuring device ( household teaspoon tablespoon ) ( 2.1 ) partial-onset seizures ( monotherapy adjunctive therapy ) 1 month < 6 months : 7 mg/kg twice daily ; increase 7 mg/kg twice daily every 2 weeks recommended dose 21 mg/kg twice daily ( 2.2 ) 6 months < 4 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 25 mg/kg twice daily ( 2.2 ) 4 years < 16 years : 10 mg/kg twice daily ; increase 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.2 ) adults 16 years older : 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.2 ) myoclonic seizures adults pediatric patients 12 years older 500 mg twice daily ; increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.3 ) primary generalized tonic-clonic seizures 6 years < 16 years : 10 mg/kg twice daily , increase increments 10 mg/kg twice daily every 2 weeks recommended dose 30 mg/kg twice daily ( 2.4 ) adults 16 years older : 500 mg twice daily , increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily ( 2.4 ) adult patients impaired renal function dose adjustment recommended , based patient \u2019 estimated creatinine clearance ( 2.5 , 8.6 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "levetiracetam tablets usp , 1000 mg white off-white modified oval shaped biconvex film-coated tablets debossed deep breakline separating \u2018 e \u2019 \u2018 13 \u2019 one side plain side . ndc : 70518-2026-00 ndc : 70518-2026-01 ndc : 70518-2026-02 packaging : 30 1 blister pack packaging : 30 1 box packaging : 1 1 pouch store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . dispense tight , light-resistant container child-resistant closure . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "levetiracetam tablets contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam is indicated for\u00a0the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients\u00a012 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3)",
    "contraindications_original": "Use the oral solution for pediatric patients with body weight \u2264 20 kg ( 2.1 ) For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) ( 2.1 ) Partial-Onset Seizures (monotherapy or adjunctive therapy) 1 Month to < 6 Months:\u00a0 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily ( 2.2 ) 6 Months to < 4 Years:\u00a0 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily ( 2.2 ) 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.2 ) Adults 16 Years and Older:\u00a0 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily ( 2.2 ) Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.3 ) Primary Generalized Tonic-Clonic Seizures 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily ( 2.4 ) Adults 16 Years and Older:\u00a0 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily ( 2.4 ) Adult Patients with Impaired Renal Function Dose adjustment is recommended, based on the patient\u2019s estimated creatinine clearance ( 2.5 , 8.6 )",
    "warningsAndPrecautions_original": "Levetiracetam Tablets USP, 1000 mg\u00a0are white to off-white modified oval shaped biconvex film-coated tablets debossed with a deep breakline separating \u2018E\u2019 and \u201813\u2019 on one side and plain on the other side.\n                  NDC: 70518-2026-00\n                  NDC: 70518-2026-01\n                  NDC: 70518-2026-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store at\u00a020\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in a tight, light-resistant container with a child-resistant closure.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema\n \n  [see\n  \n   Warnings and Precautions (5.4)].",
    "drug": [
        {
            "name": "Levetiracetam",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6437"
        }
    ]
}